AU2017353868C1 - Synthetic chimeric poxviruses - Google Patents

Synthetic chimeric poxviruses Download PDF

Info

Publication number
AU2017353868C1
AU2017353868C1 AU2017353868A AU2017353868A AU2017353868C1 AU 2017353868 C1 AU2017353868 C1 AU 2017353868C1 AU 2017353868 A AU2017353868 A AU 2017353868A AU 2017353868 A AU2017353868 A AU 2017353868A AU 2017353868 C1 AU2017353868 C1 AU 2017353868C1
Authority
AU
Australia
Prior art keywords
virus
schpxv
bsal
scpv
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017353868A
Other languages
English (en)
Other versions
AU2017353868B2 (en
AU2017353868A1 (en
Inventor
David Evans
Seth Lederman
Ryan NOYCE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharma Ltd Ireland
Original Assignee
Tonix Pharma Ltd Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Ltd Ireland filed Critical Tonix Pharma Ltd Ireland
Publication of AU2017353868A1 publication Critical patent/AU2017353868A1/en
Priority to AU2024200997A priority Critical patent/AU2024200997A1/en
Publication of AU2017353868B2 publication Critical patent/AU2017353868B2/en
Application granted granted Critical
Publication of AU2017353868C1 publication Critical patent/AU2017353868C1/en
Assigned to TONIX PHARMA LIMITED reassignment TONIX PHARMA LIMITED Request for Assignment Assignors: EVANS, DAVID, LEDERMAN, SETH, NOYCE, Ryan
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017353868A 2016-11-02 2017-11-02 Synthetic chimeric poxviruses Active AU2017353868C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024200997A AU2024200997A1 (en) 2016-11-02 2024-02-15 Synthetic chimeric poxviruses

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662416577P 2016-11-02 2016-11-02
US62/416,577 2016-11-02
US201662434794P 2016-12-15 2016-12-15
US62/434,794 2016-12-15
PCT/US2017/059782 WO2018085582A1 (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200997A Division AU2024200997A1 (en) 2016-11-02 2024-02-15 Synthetic chimeric poxviruses

Publications (3)

Publication Number Publication Date
AU2017353868A1 AU2017353868A1 (en) 2019-05-16
AU2017353868B2 AU2017353868B2 (en) 2024-02-29
AU2017353868C1 true AU2017353868C1 (en) 2024-06-06

Family

ID=62075555

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017353868A Active AU2017353868C1 (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses
AU2024200997A Abandoned AU2024200997A1 (en) 2016-11-02 2024-02-15 Synthetic chimeric poxviruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024200997A Abandoned AU2024200997A1 (en) 2016-11-02 2024-02-15 Synthetic chimeric poxviruses

Country Status (14)

Country Link
US (2) US11345896B2 (enExample)
EP (1) EP3535389A4 (enExample)
JP (3) JP2019535311A (enExample)
CN (1) CN110431228B (enExample)
AU (2) AU2017353868C1 (enExample)
BR (1) BR112019008781A2 (enExample)
CA (1) CA3042694A1 (enExample)
IL (2) IL319942A (enExample)
MX (1) MX2019005102A (enExample)
NZ (1) NZ752893A (enExample)
SG (1) SG11201903893PA (enExample)
TW (2) TWI887191B (enExample)
WO (1) WO2018085582A1 (enExample)
ZA (3) ZA201902868B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110431228B (zh) 2016-11-02 2024-04-02 戴维·埃文斯 合成嵌合痘病毒
WO2018148710A1 (en) * 2017-02-13 2018-08-16 Excision Biotherapeutics, Inc. Visualizing viral reservoirs and dissemination in vivo
JP2021522784A (ja) * 2018-05-02 2021-09-02 トニックス ファーマ ホールディングス リミテッド 合成キメラワクシニアウイルス
US20240024393A1 (en) * 2019-01-25 2024-01-25 Virocure, Inc. Pharmaceutical composition for preventing or treating cancer, comprising squirrel fibroma virus and reovirus
US20230097513A1 (en) * 2020-02-03 2023-03-30 City Of Hope Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
WO2021174142A1 (en) 2020-02-26 2021-09-02 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against sars-cov-2 virus
MX2023009008A (es) 2021-02-02 2023-10-05 Geovax Inc Constructos virales para usarse en potenciar el cebado de linfocitos t durante la vacunación.
WO2023168286A1 (en) 2022-03-01 2023-09-07 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
CN117264909B (zh) * 2023-10-25 2024-11-26 深圳湾实验室 反式互补缺陷猴痘病毒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787577A (en) 1953-12-01 1957-04-02 Lilly Co Eli Stable smallpox vaccine
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
US20070275010A1 (en) 2003-09-18 2007-11-29 Mark Feinberg Mva Vaccines
JPWO2006022215A1 (ja) 2004-08-23 2008-05-08 財団法人ヒューマンサイエンス振興財団 ＳＡＲＳ−コロナウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用
CN101020055B (zh) 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
EP2426142A3 (en) 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
US8795667B2 (en) * 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
CN105121635B (zh) 2013-04-10 2018-10-16 东源生物医药科技（上海）有限公司 突变型痘苗病毒株、其用途及其制造方法
EP3045181B1 (en) 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
JP2019528753A (ja) 2016-09-21 2019-10-17 スティーブン エイチ． ソーン， 高移動度グループｂｏｘｉ突然変異体
CN110431228B (zh) 2016-11-02 2024-04-02 戴维·埃文斯 合成嵌合痘病毒
ES2702618B2 (es) 2017-09-04 2019-10-31 Inst De Salud Carlos Iii Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica.
TW202014200A (zh) 2018-05-02 2020-04-16 賽斯 雷德曼 包含合成嵌合牛痘病毒之幹細胞及其使用方法
JP2021522784A (ja) 2018-05-02 2021-09-02 トニックス ファーマ ホールディングス リミテッド 合成キメラワクシニアウイルス

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YAO, X.-D. ET AL., VACCINIA VIRUS AND POXVIROLOGY SERIES TITLE: METHODS IN MOLECULAR BIOLOGY, vol. 269, 2004, Totowa, NJ, pages 51 - 64, XP009514225, ISBN: 978-1-59259-789-5, DOI: 10.1385/1-59259-789-0:051 *
YAO, X.-D. ET AL.: "High-Frequency Genetic Recombination and Reactivation of Orthopoxviruses from DNA Fragments Transfected into Leporipoxvirus-Infected Cells", JOURNAL OF VIROLOGY, vol. 77, no. 13, 2003, pages 7281 - 7290, XP055482181 *

Also Published As

Publication number Publication date
US12365879B2 (en) 2025-07-22
EP3535389A4 (en) 2020-06-03
IL319942A (en) 2025-05-01
CN110431228A (zh) 2019-11-08
AU2017353868B2 (en) 2024-02-29
WO2018085582A1 (en) 2018-05-11
NZ752893A (en) 2025-10-31
ZA201902868B (en) 2022-12-21
CA3042694A1 (en) 2018-05-11
SG11201903893PA (en) 2019-05-30
IL266399B2 (en) 2025-09-01
ZA202403393B (en) 2025-08-27
EP3535389A1 (en) 2019-09-11
US20180251736A1 (en) 2018-09-06
IL266399B1 (en) 2025-05-01
AU2017353868A1 (en) 2019-05-16
JP2019535311A (ja) 2019-12-12
AU2024200997A1 (en) 2024-03-07
JP2024107257A (ja) 2024-08-08
JP2022164900A (ja) 2022-10-27
CN110431228B (zh) 2024-04-02
TWI887191B (zh) 2025-06-21
MX2019005102A (es) 2019-10-30
US20230002741A1 (en) 2023-01-05
ZA202204981B (en) 2024-09-25
TW202528334A (zh) 2025-07-16
TW201819400A (zh) 2018-06-01
BR112019008781A2 (pt) 2019-07-16
US11345896B2 (en) 2022-05-31
IL266399A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
KR102631985B1 (ko) 게놈을 변형시키기 위한 조성물 및 방법
AU2017353868C1 (en) Synthetic chimeric poxviruses
DK3209381T3 (en) COMPOSITIONS COMPREHENSIVE BAKERY STUES
KR102243727B1 (ko) 유전자 표적화 및 형질 스태킹을 위한 조작된 트랜스진 통합 플랫폼 (etip)
AU2013312198B2 (en) Fluorescence activated cell sorting (FACS) enrichment to generate plants
CN114555793B (zh) 基于基因i177l缺失的新型非洲猪瘟减毒活疫苗的开发
CN116348135A (zh) 基于重组痘病毒的抗SARS-CoV-2病毒疫苗
KR20210132002A (ko) 변형된 오르토폭스 바이러스 벡터
JPH09322781A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓポリヌクレオチドおよび配列
CN112543806A (zh) 合成嵌合痘苗病毒
KR101234062B1 (ko) 림프구 내 유전자 도입용 재조합 바이러스 벡터
KR20220148823A (ko) 천연 또는 합성 dna에 의해 생산된 폭스바이러스-기반 벡터 및 그의 용도
KR20240021274A (ko) 반코마이신 내성 장구균에 대한 박테리오파지
KR102064765B1 (ko) 병원성 대장균의 증식을 억제하는 신규 박테리오파지 및 이의 용도
AU775084B2 (en) Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof
CN116670153A (zh) 允许在稳定细胞系中高效生长的非洲猪瘟疫苗的基因组缺失
AU2018256922B2 (en) Targeted gene disruption methods and immunogenic compositions
CN112261951A (zh) 包含合成嵌合痘苗病毒的干细胞及其使用方法
TWI902763B (zh) 基於重組痘病毒之抗SARS-CoV-2病毒疫苗
JP2001292771A (ja) アブラムシ共生バクテリアのゲノムｄｎａ
KR101635497B1 (ko) 종자수가 감소한 신품종 수박 및 이의 육종 방법
HK40042130A (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
HK40078138A (en) Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
CN115397447A (zh) 用于治疗葡萄球菌感染的噬菌体组合物
HK40076151A (en) Development of a novel live attenuated african swine fever vaccine based in the deletion of gene i177l

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 FEB 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 28 FEB 2024

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TONIX PHARMA LIMITED

Free format text: FORMER OWNER(S): EVANS, DAVID; NOYCE, RYAN; LEDERMAN, SETH